Reported Earnings • May 20
First quarter 2026 earnings released: EPS: €0.10 (vs €0.05 in 1Q 2025) First quarter 2026 results: EPS: €0.10 (up from €0.05 in 1Q 2025). Revenue: €300.2m (down 13% from 1Q 2025). Net income: €3.90m (up 106% from 1Q 2025). Profit margin: 1.3% (up from 0.5% in 1Q 2025). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance. Announcement • Apr 17
H&R GmbH & Co. KGaA, Annual General Meeting, May 27, 2026 H&R GmbH & Co. KGaA, Annual General Meeting, May 27, 2026, at 10:00 W. Europe Standard Time. Announcement • Apr 17
H&R GmbH & Co. KGaA announces Annual dividend, payable on May 30, 2025 H&R GmbH & Co. KGaA announced Annual dividend of EUR 0.1000 per share payable on May 30, 2025, ex-date on May 28, 2025 and record date on May 29, 2025. Announcement • Apr 16
H&R GmbH & Co. KGaA, Annual General Meeting, May 27, 2025 H&R GmbH & Co. KGaA, Annual General Meeting, May 27, 2025, at 10:00 W. Europe Standard Time. Reported Earnings • Nov 17
Third quarter 2024 earnings released: EPS: €0.09 (vs €0.20 in 3Q 2023) Third quarter 2024 results: EPS: €0.09 (down from €0.20 in 3Q 2023). Revenue: €348.7m (up 3.4% from 3Q 2023). Net income: €3.52m (down 54% from 3Q 2023). Profit margin: 1.0% (down from 2.2% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 16
Second quarter 2024 earnings released: EPS: €0.03 (vs €0.13 in 2Q 2023) Second quarter 2024 results: EPS: €0.03 (down from €0.13 in 2Q 2023). Revenue: €347.5m (flat on 2Q 2023). Net income: €1.30m (down 72% from 2Q 2023). Profit margin: 0.4% (down from 1.3% in 2Q 2023). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Jul 26
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €4.05, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 13x in the Chemicals industry in Germany. Total loss to shareholders of 56% over the past three years. Upcoming Dividend • May 22
Upcoming dividend of €0.10 per share Eligible shareholders must have bought the stock before 29 May 2024. Payment date: 31 May 2024. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (5.0%). Reported Earnings • May 17
First quarter 2024 earnings released: EPS: €0.04 (vs €0.03 loss in 1Q 2023) First quarter 2024 results: EPS: €0.04 (up from €0.03 loss in 1Q 2023). Revenue: €343.7m (down 1.5% from 1Q 2023). Net income: €1.47m (up €2.42m from 1Q 2023). Profit margin: 0.4% (up from net loss in 1Q 2023). The move to profitability was driven by lower expenses. Revenue is forecast to grow 8.9% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 30
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: €0.28 (down from €1.15 in FY 2022). Revenue: €1.35b (down 15% from FY 2022). Net income: €10.6m (down 75% from FY 2022). Profit margin: 0.8% (down from 2.7% in FY 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) also missed analyst estimates by 40%. Revenue is forecast to grow 8.0% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Declared Dividend • Mar 30
Dividend of €0.10 announced Dividend of €0.10 is the same as last year. Ex-date: 29th May 2024 Payment date: 31st May 2024 Dividend yield will be 2.1%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is well covered by both earnings (36% earnings payout ratio) and cash flows (4% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 53% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Aug 18
Second quarter 2023 earnings released: EPS: €0.13 (vs €0.58 in 2Q 2022) Second quarter 2023 results: EPS: €0.13 (down from €0.58 in 2Q 2022). Revenue: €358.1m (down 19% from 2Q 2022). Net income: €4.69m (down 78% from 2Q 2022). Profit margin: 1.3% (down from 4.9% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Upcoming Dividend • May 17
Upcoming dividend of €0.10 per share at 1.9% yield Eligible shareholders must have bought the stock before 24 May 2023. Payment date: 26 May 2023. Trailing yield: 1.9%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.6%). Valuation Update With 7 Day Price Move • Apr 27
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €5.10, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 13x in the Chemicals industry in Germany. Total returns to shareholders of 21% over the past three years. Buying Opportunity • Apr 05
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 2.5%. The fair value is estimated to be €7.73, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to decline by 12% in 2 years. Earnings is forecast to decline by 64% in the next 2 years. Reported Earnings • Apr 02
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: EPS: €1.15 (down from €1.35 in FY 2021). Revenue: €1.58b (up 32% from FY 2021). Net income: €42.7m (down 15% from FY 2021). Profit margin: 2.7% (down from 4.2% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 14%. Revenue is expected to decline by 6.7% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.8%. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Mar 01
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 3.6%. The fair value is estimated to be €7.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 92%. Revenue is forecast to decline by 9.5% in 2 years. Earnings is forecast to decline by 65% in the next 2 years. Buying Opportunity • Feb 14
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 7.3%. The fair value is estimated to be €7.59, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 92%. Revenue is forecast to decline by 9.5% in 2 years. Earnings is forecast to decline by 65% in the next 2 years. Buying Opportunity • Jan 25
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 8.5%. The fair value is estimated to be €7.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 92%. Revenue is forecast to decline by 9.5% in 2 years. Earnings is forecast to decline by 65% in the next 2 years. Price Target Changed • Nov 16
Price target decreased to €6.50 Down from €7.25, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of €6.52. Stock is down 21% over the past year. The company is forecast to post earnings per share of €1.01 for next year compared to €1.35 last year. Valuation Update With 7 Day Price Move • Oct 06
Investor sentiment improved over the past week After last week's 16% share price gain to €6.48, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 10x in the Chemicals industry in Germany. Total returns to shareholders of 8.0% over the past three years. Reported Earnings • Aug 17
Second quarter 2022 earnings released: EPS: €0.58 (vs €0.64 in 2Q 2021) Second quarter 2022 results: EPS: €0.58 (down from €0.64 in 2Q 2021). Revenue: €453.6m (up 43% from 2Q 2021). Net income: €21.6m (down 8.8% from 2Q 2021). Profit margin: 4.8% (down from 7.5% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 11%, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 16
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: €0.22 (up from €0.19 in 1Q 2021). Revenue: €368.8m (up 53% from 1Q 2021). Net income: €8.09m (up 12% from 1Q 2021). Profit margin: 2.2% (down from 3.0% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 3.8%. Over the next year, revenue is forecast to grow 6.7%, compared to a 6.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Price Target Changed • Apr 27
Price target decreased to €7.25 Down from €8.25, the current price target is provided by 1 analyst. New target price is 21% above last closing price of €6.00. Stock is down 18% over the past year. The company is forecast to post earnings per share of €0.48 for next year compared to €1.35 last year. Reported Earnings • Apr 01
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: €1.35 (up from €0.24 loss in FY 2020). Revenue: €1.19b (up 35% from FY 2020). Net income: €50.2m (up €59.2m from FY 2020). Profit margin: 4.2% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 3.8%. Over the next year, revenue is forecast to grow 1.8%, compared to a 7.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 17
Third quarter 2021 earnings released: EPS €0.43 (vs €0.03 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €325.2m (up 56% from 3Q 2020). Net income: €16.0m (up €17.3m from 3Q 2020). Profit margin: 4.9% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 4% per year. Reported Earnings • May 17
First quarter 2021 earnings released: EPS €0.19 (vs €0.13 loss in 1Q 2020) The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €248.5m (down 4.2% from 1Q 2020). Net income: €7.24m (up €12.0m from 1Q 2020). Profit margin: 2.9% (up from net loss in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 24
Full year 2020 earnings released: €0.24 loss per share (vs €0.037 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €878.5m (down 19% from FY 2019). Net loss: €9.02m (loss widened €7.65m from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance. Price Target Changed • Feb 02
Price target raised to €6.65 Up from €5.90, the current price target is an average from 2 analysts. The new target price is 11% above the current share price of €6.00. As of last close, the stock is up 14% over the past year. Is New 90 Day High Low • Jan 08
New 90-day high: €5.85 The company is up 19% from its price of €4.91 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.10 per share. Is New 90 Day High Low • Nov 28
New 90-day high: €5.77 The company is up 11% from its price of €5.22 on 28 August 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.40 per share. Analyst Estimate Surprise Post Earnings • Nov 17
Revenue and earnings miss expectations Revenue missed analyst estimates by 16%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 5.7%, compared to a 3.6% growth forecast for the Chemicals industry in Germany. Reported Earnings • Nov 17
Third quarter 2020 earnings released: €0.03 loss per share The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2020 results: Revenue: €213.3m (down 22% from 3Q 2019). Net loss: €1.21m (loss narrowed 80% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 98% per year but the company’s share price has only fallen by 31% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Oct 15
New 90-day low: €4.87 The company is down 18% from its price of €5.95 on 17 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.47 per share. Announcement • Oct 05
H&R Wasag AG to Report Q3, 2010 Results on 11/12/2010 H&R Wasag AG announced that they will report Q3, 2010 results on 11/12/2010 Is New 90 Day High Low • Sep 26
New 90-day low: €5.12 The company is down 4.0% from its price of €5.31 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.43 per share.